This clinical trial is currently not recruiting patients.
Register to get notified for future clinical trials.
See other Clinical Trials
Share: Email

Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Clinical Trial stock photo

Complete the Trial Form Below:

Check eligibility to participate in the study

  • 1. Select Your Health Conditions

    Select the health conditions that are applicable to you

  • 2. Enter your zip code

    We'll show you investigators/research sites in this zip.

  • We will contact upto 3 sites within 100 Miles

Qualification Message

Unfortunately, you did not qualify for this study. See details

You may qualify for a future study, please enter your contact information below to get notified.

  • Enter your name

  • Your email helps investigators to follow up with you.

  • Your phone number helps investigators to follow up with you.

  • By clicking this button you agree to our privacy and terms of service policies. Your information is kept completely confidential and shared only with the clinical trial personnel.
Saved Successfully

Your information has been saved successfully. We will notify you incase a matching trial comes up

You might also be interested in other clinical trials in your area







Select Investigators or Research Sites to contact
  • We will contact upto 3 sites within 100 Miles
Send Message to Investigator
  • Enter your name

  • Your email helps investigators to follow up with you.

  • Your phone number helps investigators to follow up with you.

  • Click to see the preview of your message

  • By clicking this button you agree to our privacy and terms of service policies. Your information is kept completely confidential and shared only with the clinical trial personnel.

Study Description

You may be eligible for this study if you meet the following criteria:

  • Conditions: Neuroblastoma
  • Age: Between 0 - 30 Years
  • Gender: Male or Female
  • +
    Inclusion Criteria:

Participation Details

RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young patients with recurrent or resistant neuroblastoma.

Additional Information

OBJECTIVES: Primary - To determine the maximum tolerated dose of fenretinide when given as a continuous intravenous infusion in young patients with recurrent and/or resistant neuroblastoma. - To define the toxicities of this drug in these patients. - To determine the plasma pharmacokinetics of this drug in these patients. Secondary - To determine the response rate in patients treated with this drug. - To determine the bioavailability of fenretinide in normal peripheral blood mononuclear cells as a surrogate marker for drug bioavailability to tumor tissue. OUTLINE: This is a multicenter study. Patients receive fenretinide IV continuously over 120 hours on days 0-4. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Blood samples are collected periodically for pharmacokinetic analysis by high performance liquid chromatography. After completion of study treatment, patients are followed periodically.

Clinical Trial Identifier: TX78533

Trial open to limited number of participants
546 users have viewed this page
Need Help?Contact us

Send a Message to TrialX

Your Email:
Your Phone:
Your Message:
   
To Email:
Your Email:
Your Name:
Your Message:
   
Not interested in this trial? Register to get notified for future clinical trials.